Advanced therapy medicinal products (ATMPs)
5 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- INNOVATION ACTA SRL
Italian SME providing clinical trial design and regulatory support for advanced therapies, immunomodulation, and multi-center European health studies.
“Active in RESHAPE (regulatory T cell therapies, CAR-Treg), RESTORE (advanced therapy coordination), and PACE/HIPGEN (placenta-derived cell therapies).”
PrimarySMEIT9 projects - TISSUSE GMBH
Berlin biotech SME developing multi-organ-chip and bioprinted microphysiological platforms for drug testing, toxicology, and advanced therapy evaluation.
“RESHAPE develops next-generation regulatory T cell therapies; RESTORE coordinated an advanced therapies network action.”
SMEDE5 projects - TAKIS SRL
Italian biotech SME developing DNA-based cancer immunotherapy and contributing to gene therapy and targeted drug delivery research.
“Both ARDAT and TK-NEO involve advanced therapeutic modalities — gene therapy, cell therapy, and DNA-based immunotherapy platforms.”
SMEIT3 projects - EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION
European professional society providing transplant registry data and clinical expertise for blood cancer research and cell therapy development.
“T2EVOLVE covers ATMP regulatory pathways, preclinical models, and analytical monitoring for engineered T cell therapies.”
NL3 projects